A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter Combined Phase 2a/2b Study to Assess the Efficacy and Safety of BAY 1817080 in Patients With Diabetic Neuropathic Pain
Latest Information Update: 14 Sep 2023
At a glance
- Drugs Eliapixant (Primary) ; Pregabalin
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Acronyms PUCCINI
- Sponsors Bayer
- 20 Mar 2022 This trial has been completed in Czechia , according to European Clinical Trials Database record.
- 09 Feb 2022 This trial has been discontinued in Poland (End Date: 17 Dec 2021), according to European Clinical Trials Database record.
- 04 Feb 2022 According to a Bayer media release, company announced the discontinuation of Phase II development candidate eliapixantthat was being evaluated for potential indications in endometriosis, refractory chronic cough, overactive bladder and diabetic neuropathic pain. Following a review of available data, Bayer concluded that the overall benefit no longer outweighs the risk in these indications.